Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain

What Was Tested

In this phase 4 trial, researchers set out to test Semaglutide.

SG is the most performed operation worldwide, and long-term regain after SG is well documented.

A 2026 international Delphi consensus has now standardized the definition.

It had two arms (groups): GLP 1 (active comparator) and Placebo (placebo comparator).

Matched placebo on the identical schedule.

The registry classes the interventions as drug.

More on the Plan

The biology says the combination should win.

Revision restores restriction and corrects anatomy.

It does not correct appetite biology.

Patients with poor response after MBS show blunted satiety-hormone profiles, which is exactly what GLP-1 therapy replaces.

Who Took Part

100 planned participants were the target.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: SG at least 2 years before screening. BMI of 35 kg/m² or more, or 30 kg/m² or more with at least one obesity-associated disease, and accepted for conversion to RYGB by the multidisciplinary team. Upper endoscopy and contrast imaging completed. Able to give written informed consent.

The full record lists 5 inclusion and 14 exclusion criteria; among the exclusions: staple-line leak or gastric fistula; sleeve stenosis or axial twist; hiatal hernia larger than 3 cm.

How the Study Was Run

It was run as a randomized, parallel-group and quadruple-blind study.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

The Semaglutide group and the comparison group ran side by side rather than switching.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2026-10 with completion listed for 2029-04.

It ran at 1 site in Egypt.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Percentage total weight loss (time frame: Baseline till 30 months).

It also tracked 12 secondary outcomes, for example BMI change, change in HbA1c, systolic and diastolic blood pressure, total cholesterol, LDL, HDL, and triglycerides, Operative time and Intraoperative adverse events.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Semaglutide in 100 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.